Pulmonary Arterial Hypertension-Pipeline Review, H2 2017

Pulmonary Arterial Hypertension-Pipeline Review, H2 2017


  • Products Id :- GMDHC9678IDB
  • |
  • Pages: 266
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pulmonary Arterial Hypertension-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension-Pipeline Review, H2 2017, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 9, 20, 39, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 5

Pulmonary Arterial Hypertension-Overview 6

Pulmonary Arterial Hypertension-Therapeutics Development 7

Pulmonary Arterial Hypertension-Therapeutics Assessment 20

Pulmonary Arterial Hypertension-Companies Involved in Therapeutics Development 32

Pulmonary Arterial Hypertension-Drug Profiles 55

Pulmonary Arterial Hypertension-Dormant Projects 244

Pulmonary Arterial Hypertension-Discontinued Products 246

Pulmonary Arterial Hypertension-Product Development Milestones 247

Appendix 256

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Actelion Ltd, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Aerogen Ltd, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Arena Pharmaceuticals Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Ascendis Pharma A/S, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Asklepion Pharmaceuticals LLC, H2 2017

Pulmonary Arterial Hypertension-Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Bial-Portela & Ca SA, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Biogen Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Bristol-Myers Squibb Company, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Camurus AB, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Capricor Therapeutics Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Celsion Corp, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Celtaxsys Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Chiesi Farmaceutici SpA, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Complexa Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Eli Lilly and Company, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Galectin Therapeutics Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by GlaxoSmithKline Plc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by HitGen LTD, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Insmed Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Insys Therapeutics Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Johnson & Johnson, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Liquidia Technologies Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by MannKind Corp, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Mezzion Pharma Co Ltd, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Nippon Kayaku Co Ltd, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Nippon Shinyaku Co Ltd, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Nissan Chemical Industries Ltd, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Northern Therapeutics Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Novartis AG, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Peloton Therapeutics Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by PhaseBio Pharmaceuticals Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Pluristem Therapeutics Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Polyphor Ltd, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Pulmokine Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Reata Pharmaceuticals Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Respira Therapeutics Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Reviva Pharmaceuticals Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Savara Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Serodus ASA, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Silence Therapeutics Plc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by SteadyMed Therapeutics Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Suda Ltd, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Toray Industries Inc, H2 2017

Pulmonary Arterial Hypertension-Pipeline by United Therapeutics Corp, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Vicore Pharma AB, H2 2017

Pulmonary Arterial Hypertension-Pipeline by Vivus Inc, H2 2017

Pulmonary Arterial Hypertension-Dormant Projects, H2 2017

Pulmonary Arterial Hypertension-Dormant Projects, H2 2017 (Contd..1), H2 2017

Pulmonary Arterial Hypertension-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Actelion Ltd

Aerogen Ltd

Arena Pharmaceuticals Inc

Ascendis Pharma A/S

Asklepion Pharmaceuticals LLC

AVEO Pharmaceuticals Inc

Bial-Portela & Ca SA

Biogen Inc

Bristol-Myers Squibb Company

Camurus AB

Capricor Therapeutics Inc

Celsion Corp

Celtaxsys Inc

Chiesi Farmaceutici SpA

Chugai Pharmaceutical Co Ltd

Complexa Inc

Eli Lilly and Company

Galectin Therapeutics Inc

GlaxoSmithKline Plc

HitGen LTD

Insmed Inc

Insys Therapeutics Inc

Johnson & Johnson

Liquidia Technologies Inc

MannKind Corp

Mezzion Pharma Co Ltd

Nippon Kayaku Co Ltd

Nippon Shinyaku Co Ltd

Nissan Chemical Industries Ltd

Northern Therapeutics Inc

Novartis AG

Peloton Therapeutics Inc

PhaseBio Pharmaceuticals Inc

Pluristem Therapeutics Inc

Polyphor Ltd

Pulmokine Inc

Reata Pharmaceuticals Inc

Respira Therapeutics Inc

Reviva Pharmaceuticals Inc

Savara Inc

Serodus ASA

Silence Therapeutics Plc

SteadyMed Therapeutics Inc

Suda Ltd

Takeda Pharmaceutical Company Ltd

Toray Industries Inc

United Therapeutics Corp

Vicore Pharma AB

Vivus Inc

Pulmonary Arterial Hypertension Therapeutic Products under Development, Key Players in Pulmonary Arterial Hypertension Therapeutics, Pulmonary Arterial Hypertension Pipeline Overview, Pulmonary Arterial Hypertension Pipeline, Pulmonary Arterial Hypertension Pipeline Assessment

select a license
Single User License
USD 2000 INR 137240
Site License
USD 4000 INR 274480
Corporate User License
USD 6000 INR 411720

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com